TICKERNERD
Menu
EDSAEDSAHealthcare · Biotechnology

EDSA Stock Forecast: Edesa Biotech, Inc. Price Predictions for 2026-2027

Last close, 23 Oct 2026
$2.72
−1.45% on the day

The 2 Wall Street analysts covering Edesa Biotech, Inc. hold a median 12-month price target of $19 — +598.5% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 41 of 100 as at 24 Oct 2026 — in the lower half.

Market cap
$37.4M
Ticker Nerd rank
41/ 100
Median analyst target
$19
Analysts covering
2
Revenue$0.0
Operating income−$5.4M
Net income−$5.4M
Free cash flow−$3.1M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+5.8%
1M
−31.5%
YTD
+91.5%
1Y
+1.1%
From 52W high
−85.1%
From 52W low
+240.0%
$1
$18
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

EDSA stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Edesa Biotech, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 24 Oct 2026
41/ 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
83
Accruals
79
Issuance
64
Volatility
57
Momentum
52
Value
41
Quality
31
Revisions
26
Growth
17

Size (83): Smaller than most of the companies we track.

Growth (17): Sales and profits are flat, shrinking, or growing more slowly than they were.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

EDSA stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on EDSA, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0$5$10$15$20Jan 26Apr 26Jul 26Oct 26EDSAHigh $21Median $19Low $9

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says2 analysts
2 Buy0 Hold0 Sell
Low $9Median $19High $21

The green dot is the last close — the median target sits +598.5% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
3 Nov 2025HC Wainwright & Co.ReiteratesBuy$5.00
3 Nov 2025HC Wainwright & Co.ReiteratesBuy—
27 June 2025HC Wainwright & Co.AssumesBuy$5.00
13 Mar 2025HC Wainwright & Co.ReiteratesBuy—
20 Aug 2024HC Wainwright & Co.ReiteratesBuy$21
28 June 2024HC Wainwright & Co.ReiteratesBuy$21
14 Feb 2024HC Wainwright & Co.ReiteratesBuy$21
29 Nov 2023HC Wainwright & Co.MaintainsBuy$70 → $21
22 Nov 2023HC Wainwright & Co.ReiteratesBuy$10
12 Oct 2023Brookline CapitalMaintainsBuy$57
15 Aug 2023HC Wainwright & Co.MaintainsBuy$16 → $10
24 May 2023HC Wainwright & Co.ReiteratesBuy$16
15 Mar 2023HC Wainwright & Co.ReiteratesBuy$16
14 Feb 2023HC Wainwright & Co.ReiteratesBuy$16
20 Dec 2021HC Wainwright & Co.InitiatesBuy$16

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

EDSA appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,600 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track, part by part, and one part in full with each verdict.

Free. Unsubscribe any time.

Performance

EDSA vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 23 Oct 2026, Edesa Biotech, Inc. returned +1.1% against +14.3% for the S&P 500, dividends included.

EDSA vs S&P 500, last 12 monthsTotal return, rebased to 100
0200400600Jan 26Apr 26Jul 26Oct 26EDSAS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

EDSA analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
0
Analysts cutting
2
Fundamentals

Edesa Biotech, Inc. (EDSA) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−2.1×

Cheaper than 86% of US stocks

Price / sales
—
Price / book
67.6×

Cheaper than 2% of US stocks

EV / EBITDA
−1.7×

Cheaper than 72% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−122.9%

Higher than 11% of US stocks

Return on assets
−66.4%

Higher than 5% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Edesa Biotech, Inc. (EDSA) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Edesa Biotech, Inc. has a market value of $37.4M and an enterprise value of $24.8M.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$14.1M.

  • Free cash flow in the twelve months to 30 June 2026: −$8.9M.

  • Shares outstanding: 9.6M.

  • Trailing P/E: −2.1×; forward P/E: −2.7× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Edesa Biotech, Inc. employs 17 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 24 Oct 2026

Data provided by Twelve Data

Peers

EDSA vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
EDSAEdesa Biotech, Inc.$37.4M41
EXOZeXoZymes, Inc.$37.1M13
DWTXDogwood Therapeutics, Inc.$38.1M39
VERUVeru, Inc.$38.2M56
ACETAdicet Bio, Inc.$38.2M37
INMBINmune Bio, Inc.$38.8M52
ALDXAldeyra Therapeutics, Inc.$39.2M39

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Edesa Biotech, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest EDSA news & analysis

Edesa Biotech Announces FDA IND Clearance for Phase 2 Vitiligo Study

GlobeNewsWire · 15 Oct 2026positive

Edesa Biotech said the FDA cleared its IND application for a Phase 2 study of EB06 in vitiligo, allowing recruitment to expand to the United States. Recruitment is underway in Canada, and the company expects U.S. sites to begin enrolling next quarter, with topline data anticipated in fourth-quarter 2027.

Why it matters — The clearance enables U.S. participation in the study and marks a development milestone for Edesa’s EB06 program.

Edesa Biotech Announces Pricing of $25.0 Million Public Offering

GlobeNewsWire · 20 Aug 2026neutral

Edesa Biotech announced the pricing of a $25.0 million underwritten public offering of common shares, pre-funded warrants, and accompanying common share warrants. The offering includes an underwriters' 30-day option to purchase additional shares and warrants.

Why it matters — The offering provides Edesa with approximately $25.0 million in gross proceeds to fund its clinical-stage operations.

Edesa Biotech Announces Proposed Public Offering

GlobeNewsWire · 19 Aug 2026neutral

Edesa Biotech announced it has commenced an underwritten public offering of its common shares (or pre-funded warrants in lieu thereof) and accompanying common share warrants. The company also expects to grant underwriters a 30-day option to purchase up to 15% more shares and warrants; the offering is subject to market and other conditions with no assurance of completion, size, or terms.

Why it matters — A proposed public offering could affect Edesa's share structure and capital position, so investors tracking EDSA will watch for details on the offering's size and terms.

Edesa Biotech Reports Fiscal 3rd Quarter 2026 Results

GlobeNewsWire · 13 Aug 2026neutral

Edesa Biotech reported financial results for the fiscal third quarter and nine months ended June 30, 2026, and provided a business update. The company focuses on developing host-directed therapeutics for immuno-inflammatory diseases.

Why it matters — The quarterly report offers EDSA watchers a routine update on the company's financial position and operational progress.

FAQ

Frequently asked questions about EDSA stock

What is the EDSA stock price forecast for 2026-2027?

The 2 Wall Street analysts covering Edesa Biotech, Inc. have a median 12-month price target of $19, with estimates ranging from $9 to $21. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is EDSA stock a buy right now?

Of the 2 analysts covering Edesa Biotech, Inc., 2 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Edesa Biotech, Inc. 41 out of 100 across roughly 4,600 US stocks as at 24 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank EDSA?

As at 24 Oct 2026, Edesa Biotech, Inc. ranks 41 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (83 of 100).

Will EDSA stock go up?

No one can know that. What the data says: the median 12-month target from 2 analysts implies +598.5% from the last close, and Ticker Nerd's factor model ranks Edesa Biotech, Inc. 41 out of 100 as at 24 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the EDSA stock forecast for 2030?

No analyst covering Edesa Biotech, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for EDSA are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $9 to $21 over the next 12 months.

How has EDSA stock performed over the past year?

Edesa Biotech, Inc. returned +1.1% over the 12 months to 23 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Edesa Biotech, Inc. do?

Edesa Biotech, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for inflammatory and immune-related diseases.

What is the latest news on EDSA?

The most recent item we track (GlobeNewsWire, 15 Oct 2026): "Edesa Biotech Announces FDA IND Clearance for Phase 2 Vitiligo Study". Edesa Biotech said the FDA cleared its IND application for a Phase 2 study of EB06 in vitiligo, allowing recruitment to expand to the United States. Recruitment is underway in Canada, and the company expects U.S. sites to begin enrolling next quarter, with topline data anticipated in fourth-quarter 2027.

Company

About Edesa Biotech, Inc.

Edesa Biotech, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for inflammatory and immune-related diseases. Edesa Biotech’s current pipeline centers on host-directed and targeted therapies designed for medical dermatology and respiratory conditions, including investigational programs for acute respiratory distress syndrome, chronic allergic contact dermatitis, vitiligo, systemic sclerosis, and pulmonary fibrosis. The company’s work includes monoclonal antibody and topical treatment candidates intended to modulate immune pathways and address conditions with significant unmet medical needs. Edesa Biotech operates as a research and development organization, advancing its product candidates through clinical studies and related regulatory activities. Headquartered in Markham, Ontario, Canada, the company plays a specialized role in the biotechnology sector by focusing on diseases driven by dysregulated inflammatory and immune responses.

CEO Dr. Pardeep Nijhawan FRCPC, M.D. · 17 employees · Canada · https://www.edesabiotech.com